Drug Type Contrast agent, Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms N-(E)-fluorobutenyl-3beta-(para-halo-phenyl)nortropanes 12(Emory University) |
Target |
Action modulators, enhancers |
Mechanism DAT modulators(Dopamine transporter modulators), P2Y12 receptor modulators(Purinergic receptor P2Y12 modulators), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Central nervous system injury | Preclinical | Germany | 25 Jul 2025 | |
| Neuropsychiatric syndrome | Preclinical | United States | 12 Aug 2010 |





